Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Secures £451,250 to continue its Phase 1 Clinical Trials And Director's Dealing
LONDON, UK / ACCESS Newswire / June 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ('Hemogenyx Pharmaceuticals' or the 'Company') is pleased to announce that it has raised gross proceeds of £451,250 (before expenses) via an allotment to Vladislav Sandler of 250,000 new ordinary shares of £0.01 each ('New Ordinary Shares') at an issue price of 180.5p (the 'Issue Price').
The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ('R/R AML'). As shareholders will be aware, the first two patients have now been infused with HG-CT-1.
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit the New Issue Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.
Consequentially, this fundraise involves the acceptance by Vladislav Sandler, CEO and director of the Company to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the 'Purchaser').
Warrants
Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence ('Exercise Price'), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.
Total Voting Rights
Application will be made for the 250,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 13 June ('Admission').
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,593,539.
The above figure of 4,593,539 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
'We are pleased to have secured funding from a committed investor at a premium to the prevailing market price - an indication of their confidence in the long-term potential of Hemogenyx and our HG-CT-1 program. This support enables us to continue advancing our Phase I clinical trial without undue dilution and at a pivotal moment in the development of our therapy for relapsed/refractory AML.'
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Director's Dealing Notification
Enquiries:
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
British fintech champion to ditch main listing in London
The £12bn fintech champion Wise is to abandon its primary listing in Britain for the US, dealing a blow to London's beleaguered stock market. Wise told investors on Thursday that it would move its main listing to the US, claiming it would help the company grow faster and attract more investment. It will be seen as a snub to the London Stock Exchange (LSE), which has been battling an exodus of companies amid concerns over poor liquidity and excess governance. Kristo Käärmann, Wise's chief executive. said: 'We believe the addition of a primary US listing would help us accelerate our mission and bring substantial strategic and capital market benefits to Wise and our owners.' He claimed the US was 'the biggest market opportunity in the world for our products'. The international payments firm debuted on the LSE in 2021. Its shares have risen by around 20pc since then. It said retail and institutional investors in the US were currently unable to buy shares and said the move would allow current shareholders 'greater flexibility' – as well as potentially allowing it to be included in American indices. Switching a company's main listing does not affect the number of shares. However, it can have a huge effect on its visibility and its ability to attract investors and raise capital. Different markets also have varying fees, governance and financial requirements. News of Wise's plan to quit the British public markets follows just days after the £1.1bn drug firm Indivior, which makes opioid addiction treatments, said it too would quit London to focus solely on New York. Other companies to have made similar moves include the gambling giant Flutter, which switched its main listing to New York last year to capitalise on the explosion of the American sports betting market, and the Cambridge-based tech firm Arm. Wise's announcement came as it unveiled a 15pc rise in revenues to £1.2bn on Thursday for the year to April. Shares surged by more than 7pc as markets opened as investors welcomed the news of its impending move. Last month the US private equity billionaire Orlando Bravo claimed the London stock market was in need of 'major' reforms to be able to compete against other international markets. He argued that overly tight rules on acquiring British companies have made them less appealing to US buyers. Mr Bravo, who runs the eponymous firm Thomas Bravo and has bought several British firms himself in recent years, claimed doing so would improve valuations. Speaking earlier this year, the head of the London Stock Exchange Group (LSEG), David Schwimmer, insisted that London's position compared to other global markets meant it would be able to ride out the storm it faces. He said: 'London is probably third or fourth in the world in terms of being a capital-raising centre. 'There's lots of questions and focus on IPO [initial public offering] but if you look at the capital raised in general, including the follow-ons, this is a very healthy market with plentiful liquidity and lots of activity.' He argued there was little evidence of companies doing better after moving their listings. 'If you take a look at the companies that have gone from the UK to list in New York over the last 10 years it's about 20 companies. Of those 20, four are trading up, nine are delisted, and the rest are trading down by an average of over 80pc.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Could This Be a Sign Warren Buffett May Be Unloading 1 of His Biggest Stock Holdings?
Berkshire Hathaway is no longer going to have a position on Kraft's board of directors. This comes as the food company is evaluating strategic transactions. Kraft has struggled to grow its business, and its future prospects don't look all that great. 10 stocks we like better than Kraft Heinz › Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), invests in many top blue chip stocks. They are mainly centered around financial services, consumer goods, and oil and gas. And while there may be some changes in smaller positions within Berkshire's holdings, the top 10 stocks don't normally see a lot of turnover. But with Buffett stepping down as CEO this year, there could be some more significant changes on the way. And there's a move that Berkshire recently made that stood out to me, one that could signify the end of its position in one of its largest holdings: Kraft Heinz (NASDAQ: KHC). In a press release dated May 20, Kraft announced that its board and leadership team are looking at "potential strategic transactions to unlock shareholder value." It also noted that Berkshire Hathaway's two representatives on the board -- Timothy Kenesey and Alicia Knapp -- would be stepping down. Thus, at a critical time in Kraft's business, when the company is struggling to grow (its sales were down 3% last year) and possibly looking at making significant changes, Berkshire appears to be distancing itself from the consumer goods company. It's not hard to see why Kraft may need to make a move. Its top line has struggled to grow in recent years, and as the government focuses on healthier eating options and people are using GLP-1 weight loss drugs to shed pounds and curb their appetites, the company's growth prospects aren't looking so great. If Berkshire isn't involved in these critical strategic decisions, the writing may be on the wall for its investment in Kraft. For years, it hasn't made a whole lot of sense as to why Kraft remains one of Berkshire's top holdings. It makes up just over 3% of Berkshire's overall portfolio, making it the eighth-largest position, behind Occidental Petroleum, Moody's, and Chevron. Kraft pays a dividend, which Buffett likes, but it has been a bad investment over the years, even despite the payout. In five years, the stock has declined by 12% and when you include its dividend, the total return is only 10%. That is a pitiful performance when you compare it against the S&P 500, which has more than doubled in value over that time frame when including dividends. For a forward-looking investor such as Buffett, the future doesn't look all that promising for Kraft either, whose iconic Mac & Cheese brand has become associated with unhealthy eating habits due to its processed ingredients and high sodium. Given all the question marks around the business, it wouldn't surprise me in the least to see Berkshire finally exit its position in Kraft. Berkshire and 3G Capital (which has since sold its stake) bought Heinz back in 2013, a few years before it merged with Kraft. If Berkshire sells its stake in Kraft, that could send the stock into a deeper free fall. But regardless of whether that happens or not, this is a stock that you may be better off avoiding. Simply because an investment is or isn't in Buffett's portfolio shouldn't determine whether you buy or sell it. Ultimately, it's important to make your own investment decisions based on your own goals and objectives, as they will be different from Buffett's and Berkshire's. And if you're looking at where Kraft's business is heading, the outlook doesn't look terribly promising. Even the stock's 6% yield may not prove to be safe in the long run, especially if its sales and profits decline. Without more compelling growth prospects, this stock may continue to be a bad buy for the foreseeable future. Before you buy stock in Kraft Heinz, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Kraft Heinz wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Chevron, and Moody's. The Motley Fool recommends Kraft Heinz and Occidental Petroleum. The Motley Fool has a disclosure policy. Could This Be a Sign Warren Buffett May Be Unloading 1 of His Biggest Stock Holdings? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Ensurge Micropower ASA - Registration of Share Capital Increase
Reference is made to the announcement by Ensurge Micropower ASA (the "Company") on 19 May 2025 regarding exercise of 167,000 vested incentive subscription rights under the Company's 2022 Subscription Rights Plan and exercise of 200,000 vested incentive subscription rights under the Company's 2023 Subscription Rights Plan and the resulting issuance of a total of 367,000 new shares in the Company. The share capital increase associated with the above has now been duly registered in the Register of Business Enterprises. Following the share capital increase, the Company's share capital is NOK 397,790,160.50 divided into 795,580,321 shares, each share having a par value of NOK 0.50. About Ensurge Micropower Ensurge is energizing innovation with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery. With a workforce of forty top-tier specialists based in the world's technology capital, Silicon Valley, Ensurge has developed a future-oriented and innovative microbattery technology. The microbattery is ideal for form-factor-constrained applications, including hearables, digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company's state-of-the-art manufacturing facility combines patented process technology and materials innovation, with the scale of roll-to-roll production methods, to bring the advantages of Ensurge technology to established and expanding markets. Ensurge's production facilities are optimized for prototyping and small-scale manufacturing. To scale efficiently, we aim to outsource the production of the resulting intellectual property (IP) to specialized partners with industrial manufacturing expertise. Ensurge is listed on the Norwegian stock exchange and is financed out of Norway by strong and reputable financial investors, reflecting both a strategic investment and a robust transatlantic collaboration. For more information: Lars Eikeland, Chief Executive Officer E- mail: (mailto: This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
